CIENCIASMEDICASNEWS: High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial - The Lancet Respiratory Medicine

sábado, 12 de febrero de 2022

High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial - The Lancet Respiratory Medicine

High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial - The Lancet Respiratory Medicine

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)